Literature DB >> 30481388

Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.

Antoine Deschildre1, Juliette Roussel1, Elodie Drumez2, Rola Abou-Taam3, Cinthia Rames4, Pascal Le Roux5, Guillaume Pouessel6, Manuëla Scalbert7, Cecile Bonnel8, Sarah Mitha9, Sophie Boileau10, Clémence Mordacq1, Caroline Thumerelle1, Julien Labreuche2, Stéphanie Lejeune1, Christophe Marguet11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30481388     DOI： 10.1111/all.13678

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  8 in total

Review 1.  Resolution of allergic asthma.

Authors:  Susetta Finotto
Journal:  Semin Immunopathol       Date:  2019-11-08       Impact factor: 9.623

Review 2.  Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update.

Authors:  Gian Luigi Marseglia; Amelia Licari; Maria Angela Tosca; Giorgio Ciprandi
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-11-13       Impact factor: 0.885

3.  Inflammatory Remission in T2 Severe Asthma.

Authors:  Manuel J Rial; Javier Domínguez-Ortega
Journal:  Front Allergy       Date:  2022-05-30

4.  Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.

Authors:  Molly M Jeffery; Jonathan W Inselman; Jacob T Maddux; Regina W Lam; Nilay D Shah; Matthew A Rank
Journal:  J Allergy Clin Immunol Pract       Date:  2021-02-27

Review 5.  Novel therapeutic targets for allergic airway disease in children.

Authors:  Alessandro Giallongo; Giuseppe Fabio Parisi; Amelia Licari; Giulio Pulvirenti; Caterina Cuppari; Carmelo Salpietro; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Drugs Context       Date:  2019-07-09

Review 6.  Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma.

Authors:  Nicola A Hanania; Robert Niven; Pascal Chanez; Deschildre Antoine; Pascal Pfister; Lorena Garcia Conde; Xavier Jaumont
Journal:  World Allergy Organ J       Date:  2022-09-25       Impact factor: 5.516

7.  Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.

Authors:  Giorgio Walter Canonica; Giorgio Lorenzo Colombo; Paola Rogliani; Pierachille Santus; Claudia Pitotti; Sergio Di Matteo; Chiara Martinotti; Giacomo Matteo Bruno
Journal:  Risk Manag Healthc Policy       Date:  2020-01-22

Review 8.  Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective.

Authors:  Michele Ghezzi; Elena Pozzi; Luisa Abbattista; Luisa Lonoce; Gian Vincenzo Zuccotti; Enza D'Auria
Journal:  Children (Basel)       Date:  2021-12-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.